vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与DOMO, INC.（DOMO）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是DOMO, INC.的1.9倍（$152.6M vs $79.4M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -13.1%，领先47.6%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -0.5%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $1.1M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -0.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Domo股份有限公司是总部设在美国犹他州美国福克的美国云软件企业，主营人工智能、商业智能与数据可视化业务，属于SaaS（软件即服务）企业，核心产品可帮助企业各层级决策者在极少IT介入的情况下，实时获取业务数据，支撑决策开展。
CPRX vs DOMO — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $79.4M |
| 净利润 | $52.7M | $-10.4M |
| 毛利率 | 82.9% | 74.2% |
| 营业利润率 | 40.5% | -8.7% |
| 净利率 | 34.5% | -13.1% |
| 营收同比 | 7.6% | -0.5% |
| 净利润同比 | -5.8% | 44.6% |
| 每股收益（稀释后） | $0.40 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $79.4M | ||
| Q3 25 | $148.4M | $79.7M | ||
| Q2 25 | $146.6M | $80.1M | ||
| Q1 25 | $141.4M | $78.8M | ||
| Q4 24 | $141.8M | $79.8M | ||
| Q3 24 | $128.7M | $78.4M | ||
| Q2 24 | $122.7M | $80.1M | ||
| Q1 24 | $98.5M | $80.2M |
| Q4 25 | $52.7M | $-10.4M | ||
| Q3 25 | $52.8M | $-22.9M | ||
| Q2 25 | $52.1M | $-18.1M | ||
| Q1 25 | $56.7M | $-17.7M | ||
| Q4 24 | $55.9M | $-18.8M | ||
| Q3 24 | $43.9M | $-19.5M | ||
| Q2 24 | $40.8M | $-26.0M | ||
| Q1 24 | $23.3M | $-18.7M |
| Q4 25 | 82.9% | 74.2% | ||
| Q3 25 | 84.7% | 74.8% | ||
| Q2 25 | 85.9% | 74.2% | ||
| Q1 25 | 87.3% | 74.4% | ||
| Q4 24 | 84.7% | 75.0% | ||
| Q3 24 | 85.0% | 74.3% | ||
| Q2 24 | 87.4% | 74.1% | ||
| Q1 24 | 87.3% | 76.3% |
| Q4 25 | 40.5% | -8.7% | ||
| Q3 25 | 44.7% | -9.1% | ||
| Q2 25 | 45.2% | -17.9% | ||
| Q1 25 | 44.8% | -15.6% | ||
| Q4 24 | 44.3% | -13.9% | ||
| Q3 24 | 39.6% | -18.5% | ||
| Q2 24 | 44.2% | -26.8% | ||
| Q1 24 | 27.5% | -16.6% |
| Q4 25 | 34.5% | -13.1% | ||
| Q3 25 | 35.6% | -28.8% | ||
| Q2 25 | 35.6% | -22.5% | ||
| Q1 25 | 40.1% | -22.4% | ||
| Q4 24 | 39.4% | -23.5% | ||
| Q3 24 | 34.1% | -24.9% | ||
| Q2 24 | 33.2% | -32.5% | ||
| Q1 24 | 23.6% | -23.3% |
| Q4 25 | $0.40 | $-0.25 | ||
| Q3 25 | $0.42 | $-0.56 | ||
| Q2 25 | $0.41 | $-0.45 | ||
| Q1 25 | $0.45 | $-0.45 | ||
| Q4 24 | $0.44 | $-0.48 | ||
| Q3 24 | $0.35 | $-0.51 | ||
| Q2 24 | $0.33 | $-0.69 | ||
| Q1 24 | $0.19 | $-0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | — |
| 总债务越低越好 | — | $124.2M |
| 股东权益账面价值 | $954.3M | $-191.9M |
| 总资产 | $1.1B | $201.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | — | ||
| Q3 25 | $689.9M | — | ||
| Q2 25 | $652.8M | $47.2M | ||
| Q1 25 | $580.7M | $45.3M | ||
| Q4 24 | $517.6M | — | ||
| Q3 24 | $442.3M | — | ||
| Q2 24 | $375.7M | $61.2M | ||
| Q1 24 | $310.4M | $60.9M |
| Q4 25 | — | $124.2M | ||
| Q3 25 | — | $121.9M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $117.7M | ||
| Q4 24 | — | $115.6M | ||
| Q3 24 | — | $115.2M | ||
| Q2 24 | — | $114.1M | ||
| Q1 24 | — | $113.5M |
| Q4 25 | $954.3M | $-191.9M | ||
| Q3 25 | $920.2M | $-191.5M | ||
| Q2 25 | $856.0M | $-178.7M | ||
| Q1 25 | $794.3M | $-177.2M | ||
| Q4 24 | $727.6M | $-171.2M | ||
| Q3 24 | $660.9M | $-166.4M | ||
| Q2 24 | $608.7M | $-163.5M | ||
| Q1 24 | $561.4M | $-153.5M |
| Q4 25 | $1.1B | $201.6M | ||
| Q3 25 | $1.1B | $195.7M | ||
| Q2 25 | $971.9M | $189.7M | ||
| Q1 25 | $908.9M | $214.3M | ||
| Q4 24 | $851.4M | $190.2M | ||
| Q3 24 | $772.0M | $197.8M | ||
| Q2 24 | $706.4M | $204.4M | ||
| Q1 24 | $646.7M | $225.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $3.4M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $1.1M |
| 自由现金流率自由现金流/营收 | 29.4% | 1.4% |
| 资本支出强度资本支出/营收 | 0.0% | 2.9% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $9.9M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $3.4M | ||
| Q3 25 | $32.4M | $3.4M | ||
| Q2 25 | $71.3M | $4.0M | ||
| Q1 25 | $60.0M | $8.9M | ||
| Q4 24 | $70.9M | $-13.7M | ||
| Q3 24 | $72.9M | $-6.2M | ||
| Q2 24 | $64.1M | $1.9M | ||
| Q1 24 | $31.9M | $5.4M |
| Q4 25 | $44.9M | $1.1M | ||
| Q3 25 | — | $1.0M | ||
| Q2 25 | $71.3M | $1.0M | ||
| Q1 25 | — | $6.7M | ||
| Q4 24 | $70.8M | $-16.2M | ||
| Q3 24 | $72.6M | $-8.4M | ||
| Q2 24 | $64.1M | $-625.0K | ||
| Q1 24 | $31.7M | $2.9M |
| Q4 25 | 29.4% | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | 48.6% | 1.3% | ||
| Q1 25 | — | 8.5% | ||
| Q4 24 | 49.9% | -20.3% | ||
| Q3 24 | 56.4% | -10.7% | ||
| Q2 24 | 52.3% | -0.8% | ||
| Q1 24 | 32.2% | 3.6% |
| Q4 25 | 0.0% | 2.9% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 3.7% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.1% | 3.2% | ||
| Q3 24 | 0.2% | 2.8% | ||
| Q2 24 | 0.0% | 3.2% | ||
| Q1 24 | 0.2% | 3.1% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
